Liposomes like Rg3-PTX-LPs target resistant breast cancer cells and reverse drug resistance, achieving significant tumor inhibition. ApoA1-modified cationic liposomes enhance doxorubicin uptake and minimize adverse effects. Here, APOA1 is linked to breast carcinoma.